| abstract |
The primary object of the invention is the enhancer sequences from the protein sequences of various retroviral envelopes (gp41), which improve the pharmacokinetic properties of a core polypeptide linked to them. The invention is based on the result that when the peptide sequences of the invention are linked to any core polypeptide, the hybrid polypeptide thus obtained exhibits improved pharmacokinetic properties, such as a longer half-life than the core polypeptide alone. The present invention further provides such hybrid polypeptides, the process for their preparation, and the core polypeptides. Hybrid polypeptides comprise a core polypeptide and one or more attached enhancer peptide sequences. The hybrid polypeptide of the present invention is preferably used to inhibit viral infections and / or cellular fusion phenomena caused by viruses. HE |